- Targeting Ebitda breakeven next year
- Downgrade to full-year sales outlook
Falling sales and widening losses are almost never good news for a company’s share price. Cell and gene therapy group Oxford Biomedica (OXB) saw its shares rise 11 per cent on results day, having struggled so far this year, after it unveiled underwhelming figures but promised better times lie ahead in 2024.